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Background: The number of patients who have undergone intravitreal injections has increased 
enormously in recent years, but a consensus is still lacking on prophylaxis for endophthalmitis. 
The aim of this prospective, observational study was to evaluate the prophylactic effect of 
azithromycin eye drops versus ofloxacin eye drops.
Methods: The study was conducted in five hospitals in Spain and included all patients under-
going intravitreal injections of triamcinolone, bevacizumab, ranibizumab, or pegaptanib over 
one year. Patients received azithromycin 15 mg/g eye drops (twice daily on the day prior to 
injection and for another 2 days) or ofloxacin 3 mg/g eye drops (every 6 hours on the day prior 
to injection and for another 7 days).
Results: In the azithromycin group, there were 4045 injections in 972 eyes of 701 patients. 
In the ofloxacin group, there were 4151 injections in 944 eyes of 682 patients. There were two 
cases of endophthalmitis (0.049%) in the azithromycin group and five (0.12%) in the ofloxacin 
group. The odds ratio of presenting with endophthalmitis in the ofloxacin group compared with 
the azithromycin group was 2.37 (95% confidence interval [CI] 1.32–3.72, P , 0.001). There 
were two cases of noninfectious uveitis after triamcinolone injection in the azithromycin group 
(0.049%) and two (0.048%) in the ofloxacin group; no significant differences were observed 
(odds ratio 0.902, 95% CI 0.622–1.407, P = 0.407). Conjunctival hyperemia was observed in 
12 cases in the azithromycin group and none in the ofloxacin group.
Conclusion: The risk of endophthalmitis was significantly greater with ofloxacin than with 
azithromycin. These findings provide a valuable addition to the ever-increasing pool of infor-
mation on endophthalmitis prophylaxis after intravitreal injection, although further large-scale 
studies are required to provide definitive conclusions.
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Introduction
The number of patients who have undergone intravitreal injections has increased 
enormously in recent years, partly due to the greater number of pathologies in which 
these injections are indicated (diabetic retinopathy, age-related macular degeneration, 
diabetic or retinal venous occlusion, macular edema, or uveitis) and partly because of 
the growing number of available drugs that can be administered in this way.1 Intravitreal 
antibiotics were first used at the end of the 1990s and early in the new millennium, 
and new drugs are constantly being commercialized for intravitreal injection, such as 
corticosteroids and anti-vascular endothelial growth factor agents. In the coming years, 
more new drugs will likely become available; slow-release drugs such as fluocinolone 
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are already approved in some territories, and intravitreal 
implants are already under consideration.  However, this 
increase in the number of intravitreal injections has also 
meant an increase in the number of complications, such as 
post-intravitreal injection endophthalmitis, over the past 
few years.2
Despite the existence of guidelines3 and a degree of con-
formity in procedures for intravitreal injection, differences 
between institutions and physicians4 have resulted in some 
variation in the rate of endophthalmitis; however, the most 
studies report rates in the range of 0.02%–0.3%.5–9
Prophylaxis for postoperative endophthalmitis after 
cataract surgery has improved in recent years with the 
postoperative administration of eye drops (such as fourth-
generation quinolones) or intracameral cephalosporin 
injection at the end of surgery.10–15 Conversely, informa-
tion is lacking on postoperative endophthalmitis prophy-
laxis after intravitreal injections.16,17 Endophthalmitis is a 
relatively rare complication of intravitreal injection and so 
controlled clinical trials require large patient samples to 
provide definitive  conclusions. At present, one approach 
for prophylaxis consists of instillation of povidone iodine 
into the conjunctival sac prior to injection, plus subsequent 
administration of antibiotic eye drops.18 The aim of this 
study was to evaluate the prophylactic effect of azithro-
mycin versus ofloxacin eye drops against endophthalmitis 
after intravitreal injection.
Materials and methods
This prospective, observational study was conducted in 
five hospitals in Spain. The study population included 
all patients undergoing intravitreal injections of 
 triamcinolone,  bevacizumab, ranibizumab, or pegaptanib 
from January 2010 to December 2010. Patients undergoing 
ocular surgery or those allergic to quinolones or macrolides 
were excluded.
Prophylactic treatment
The prophylactic protocol consisted of topical povidone 
iodine 10% on the skin of the periorbital region plus 5% on 
the conjunctiva and eyelashes for a minimum of one  minute. 
The periorbital region and eyelashes were draped and a 
sterile lid speculum, topical anesthetic, and sterile gloves 
were used. Patients were randomized to receive azithro-
mycin 15 mg/g eye drops (twice daily on the day prior to 
injection and for 2 days post-injection) or ofloxacin 3 mg/g 
eye drops (every 6 hours on the day prior to injection and 
for another 7 days).
Standard operation procedures
After prophylactic measures, the injection was made at the 
temporal inferior quadrant 4 mm from the limbus. All patients 
were examined the day before injection.
Assessments
A total of eight follow-up visits every 6 weeks were scheduled. 
A complete ophthalmologic examination was performed at 
each visit. Vitreous samples were obtained by manual vir-
trectomy before intravitreal antibiotics in patients showing 
signs of acute endophthalmitis.
Definition of acute postoperative 
endophthalmitis
A diagnosis of presumed acute endophthalmitis was made 
by the ophthalmologist according to Endophthalmitis 
 Vitrectomy Study criteria.19 All suspected cases had swollen 
eye lids, pain and an opaque vitreous.20 If a positive culture of 
 vitreous sample was obtained, the case was confirmed as acute 
endophthalmitis. The diagnosis of  pseudoendophthalmitis 
secondary to intravitreal triamcinolone injection was based 
on decreased visual acuity, without pain and with minimal red 
eye that appeared 1–3 days after the injection, with hyalitis 
and a fibrinous reaction in the anterior chamber.
Microbiological methods
Vitreous samples obtained by the ophthalmologist were 
processed immediately. A Gram stain was performed and the 
sample cultivated in Petri dishes. Antibiogram susceptibil-
ity testing was performed according to MENSURA (Mesa 
Española de Normalización de la Sensibilidad y Resistencia 
a los Antimicrobianos) criteria.21,22
Statistical analyses
Statistical analyses were performed using SPSS statistical 
software version 17.0 (SPSS Inc, Chicago, IL). Values are 
expressed as the mean ± standard deviation, and statistical 
analysis was determined using the Mann–Whitney U test.
Results
A total of 1383 patients were included. The mean patient age 
was 69.8 ± 7.55 (53–89) years in the azithromycin group and 
68.17 ± 7.83 (53–90) years in the ofloxacin group (P = 0.372). 
Females accounted for 58% of patients in both groups. There 
were no statistically significant differences between the 
groups. The drugs injected in each group are shown in Table 1. 
Again, there were no statistically  significant differences between 
the groups. In the azithromycin group, there were a total of 
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Other complications included conjunctival  hyperemia 
(12 cases with azithromycin [0.29%] and none with 
 ofloxacin), punctate keratitis (two cases with azithromycin 
and none with ofloxacin), subconjunctival hemorrhage 
(eight cases with azithromycin and six with ofloxacin) and 
a decrease in acute visual acuity with relapse a few minutes 
after intravitreal injection (three cases in each group).
Discussion
With the considerable growth in the use of intravitreal 
 injections in recent years, there has been an increasing  interest 
in determining an effective strategy for endophthalmitis 
prophylaxis.
The incidence of endophthalmitis, which is a poten-
tially vision-threatening condition, is currently unclear 
because very few studies have been conducted. Most data 
are derived from extended clinical trials that attempted 
to administer drugs intravitreally, such as the RESTORE 
(Ranibizumab Monotherapy or Combined with Laser 
versus Laser Monotherapy for Diabetic Macular Edema) 
study, in which no endophthalmitis cases were observed 
after 2415 injections23 or the Diabetic Retinopathy Clinical 
Research Network24 study in which one patient (0.9%; 95% 
CI 0.02–4.7) developed endophthalmitis after receiving 
ranibizumab.  According to the meta-analysis by Jager et al,18 
the incidence of endophthalmitis after use of intravitreal 
medicines is 0.3% per injection and 0.9% per eye. The 
Vitravene Study Group25 described two cases of endophthal-
mitis after 1791 injections (0.11%) in 330 eyes (0.60%).
A larger study was performed by McCannel et al26 who 
conducted a meta-analysis of the US literature from 2005 
to 2009 and observed a total of 52 cases of endophthal-
mitis in 105,536 injections, with an incidence of 0.049% 
(95% CI 0.038–0.065). In this study, endophthalmitis cul-
ture was negative in 24 cases (48.0% [95% CI 34.8–61.5]) 
and positive in 26 (52% [95% CI 38.5–65.2]). Of the 26 
culture-positive isolates, the causative organisms were 
coagulase-negative Staphylococcus spp. in 17 cases (65.4% 
[95% CI 46.0–80.6]), Streptococcus spp. in eight cases 
Table 1 Intravitreal injections and drugs administered
Azithromycin (n = 4045) Ofloxacin (n = 4151)
Ranibizumab 2648 2946
Bevacizumab 872 840
Pegaptanip 52 42
Triamcinolone 476 323
Table 2 Characteristics of patients with endophthalmitis
Gender Age Drug  
injected
Culture Endophthalmitis 
treatment
Azithromycin (n = 2)
Male 77 Ranibizumab S. epidermidis Intravitreal antibiotics
Female 80 Pegaptanip negative Intravitreal antibiotics
Ofloxacin (n = 5)
Male 76 Ranibizumab S. epidermidis Intravitreal antibiotics
Male 72 Ranibizumab S. epidermidis Intravitreal antibiotics + 
25-gauge vitrectomy
Female 77 Ranibizumab S. aureus Intravitreal antibiotics
Female 69 Ranibizumab negative Intravitreal antibiotics
Male 76 Ranibizumab negative Intravitreal antibiotics
Abbreviations: S. epidermidis, Staphylococcus epidermidis; S. aureus, Staphylococcus 
aureus.
Table 3 Characteristics of patients with triamcinolone reaction
Gender Age Culture Ocular pathology
Azithromycin (n = 2)
Male 78 negative Diabetic macular edema
Female 82 negative Diabetic macular edema
Ofloxacin (n = 2)
Female 71 negative Diabetic macular edema
Female 74 negative Diabetic macular edema
4045 injections in 972 eyes of 701 patients (4.16 injections 
per eye and 5.77 injections per patient). In the ofloxacin group, 
there were a total of 4151 injections in 944 eyes of 682 patients 
(4.39 injections per eye and 6.08 injections per patient).
Endophthalmitis cases
There were two cases (0.049%) of endophthalmitis (acute 
endophthalmitis and pseudoendophthalmitis) within a 
mean time of 4.37 ± 1.33 days after surgery in the azithro-
mycin group and five cases (0.12%) within a mean time of 
4.41 ± 1.29 days in the ofloxacin group. The characteristics 
of the seven cases are shown in Table 2. The risk (odds ratio) 
of presenting with endophthalmitis in the ofloxacin group 
compared with the azithromycin group was 2.37 (95% con-
fidence interval [CI] 1.32–3.72, P , 0.001). When limiting 
the analysis to culture-positive cases (one case in the azithro-
mycin group and three in the ofloxacin group), the estimated 
relative risk was 3.01 (95% CI 1.97–4.11, P , 0.001).
Adverse reactions
There were two cases of uveitis after triamcinolone injection 
in the azithromycin group (0.049%) and two cases (0.048%) 
in the ofloxacin group. No significant differences were 
observed in the statistical analysis (odds ratio 0.902, 95% 
CI 0.622–1.407, P = 0.407). No cases of raised intraocular 
pressure were recorded. The characteristics of the patients 
are shown in Table 3.
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(30.8% [95% CI 16.5–50.2]), and Bacillus cereus in one case 
(3.8% [95% CI 0.9–19.0]). The authors found a significantly 
higher number of cases due to Streptococcus species than 
after cataract surgery in the Endophthalmitis Vitrectomy 
Study. The percentage of cases with endophthalmitis in the 
current study was similar to that in the published data, at 
0.049% in the azithromycin group and 0.12% in the ofloxa-
cin group. Unlike McCannel et al,26 the most commonly 
found bacterium (three of the four positive cases) in our 
study was Staphylococcus epidermidis.
Because little is known about the incidence of endophthal-
mitis, it is unclear whether prophylactic antibiotics should be 
used. Some authors, such as Bhatt et al,27 concluded that “the 
rate of endophthalmitis after intravitreal injections admin-
istered in a clinical practice setting when aseptic technique 
is used is similar with or without the use of post injection 
antibiotics”, but their study was based on a small number of 
patients. In contrast, most scientific bodies recommend the 
use of topical antibiotics in addition to prophylactic measures 
during surgery such as povidone iodine instillation on the 
conjunctiva, draping of the periorbital region and eyelashes, 
and the use of a sterile lid speculum. However, there are few 
recommendations on antibiotic use. The Royal College of 
Ophthalmologists28 recommends a dose of antibiotics before 
injecting the drug, while the Spanish Society of Retina and 
Vitreous recommends topical antibiotic treatment after 
injection.29 The French Agence Nationale de Sécurité du 
Médicament also recently recommended topical antibiotics 
after injection, but stated that systemic administration is not 
indicated.30 They advised referring to the marketing authority 
for the substance being injected for advice on preinjection 
topical antibiotic prophylaxis.
Azithromycin was chosen for this study because it is 
a broad spectrum antibiotic that covers most commonly 
found bacteria in the environment and is more potent against 
most Gram-negative organisms than erythromycin.31,32 
Furthermore, adequate and long-lasting levels were observed 
in the conjunctiva that remained well above the minimum 
inhibitory concentration (MIC) breakpoint for susceptible 
organisms for up to 24 hours after instillation. Residual 
azithromycin levels observed 7 days after the last admin-
istration were above the MIC breakpoint of 0.5 µg/g in the 
conjunctiva and cornea. This permits topical administration 
twice daily for 3 days, resulting in significant concentrations 
in the conjunctiva and cornea for at least 7 days after final 
administration.33,34 Although azithromycin has poor intraocu-
lar penetration when given topically, its main role is via the 
elimination of periocular bacteria.
In the current study, we observed that the number of 
endophthalmitis cases was higher in the group that used 
ofloxacin (0.12%) versus the azithromycin group (0.049%), 
resulting in a significantly increased risk of endophthalmitis 
of 2.37 (P , 0.001). However, the relatively low sample size 
and incidence of endophthalmitis is one of the major limita-
tions of the study that precludes any categorical confirmation 
of the advantage of one drug over the other in the prophylaxis 
of endophthalmitis after intravitreal injection. Azithromycin-
treated patients had a somewhat higher rate of conjunctival 
hyperemia, that was nevertheless seen in less than three cases 
per 1000. There were no differences in other adverse events.
In conclusion, these findings provide a valuable addition 
to the ever-increasing pool of information on endophthalmi-
tis prophylaxis after intravitreal injection, although further 
similar large-scale studies will be required before reaching 
definitive conclusions.
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